

Supplementary Table 1. Subset of patient characteristics between the Fever group and the non-Fever group

Characteristics	Fever (N=665)	non-Fever (N=5671)	P-value
Age, mean (year)	63.2	63.8	<0.001 ¹
Age group, <i>n</i> (%)			<0.001 ²
10 (10y ≤ age < 20y)	6 (0.9)	10 (0.2)	
20 (20y ≤ age < 30y)	19 (2.9)	42 (0.7)	
30 (30y ≤ age < 40y)	28 (4.2)	153 (2.7)	
40 (40y ≤ age < 50y)	40 (6.0)	420 (7.4)	
50 (50y ≤ age < 60y)	112 (16.8)	1173 (20.7)	
60 (60y ≤ age < 70y)	211 (31.7)	1880 (33.2)	
70 (70y ≤ age < 80y)	211 (31.7)	1721 (30.3)	
80 (80y ≤ age < 90y)	37 (5.6)	269 (4.7)	
90 (90y ≤ age < 100y)	1 (0.2)	3 (0.1)	
Past medical history of malignancy, <i>n</i> (%)			
Lung	408 (76.7)	3,391 (74.2)	0.002 ²
Gastrointestinal	33 (6.2)	319 (7.0)	
Hematologic	19 (3.6)	54 (1.2)	
Head and neck	14 (2.6)	109 (2.4)	
Breast	12 (2.3)	126 (2.8)	
HBP	11 (2.1)	142 (3.1)	
Esophageal	10 (1.9)	122 (2.7)	
Urologic	6 (1.1)	117 (2.6)	
Brain	3 (0.6)	42 (0.9)	
Gynecologic	2 (0.4)	35 (0.8)	
Others [†]	5 (0.9)	45 (1.0)	
Unknown-origin	9 (1.7)	67 (1.5)	
Past medical history of tuberculosis, <i>n</i> (%)			
Pulmonary	36 (69.2)	165 (73.3)	0.002 ²

Lymphadenitis	8 (15.4)	38 (16.9)
Miliary	3 (5.8)	0
Gastrointestinal	1 (1.9)	1 (0.4)
Pleurisy	1 (1.9)	13 (5.8)
Cardiac	1 (1.9)	3 (1.3)
Others [‡]	2 (3.8)	2 (0.9)
Unspecified	0	3 (1.3)

HBP = hepatobiliary and pancreatic. [†]This included musculoskeletal, skin, thymus, and cardiac malignancy.

[‡]This included spinal and endobronchial tuberculosis, and tuberculous meningitis.

¹Student's t-test; ²Chi-squared test; *P* < 0.05 is shown in bold.

Supplementary Table 2. Comparison of laboratory findings before and after EBUS-TBNA between the Fever group and the non-Fever group

Laboratory	Before EBUS-TBNA			After EBUS-TBNA		
	Fever	non-Fever	<i>P</i> -value	Fever	non-Fever	<i>P</i> -value
	(N=665)	(N=5671)	(t-test)	(N = 665)	(N = 5671)	(t-test)
CRP, mg/dL	4.4±5.6	1.6±3.1	<0.001	6.5±5.8	4.1±5.6	<0.001
WBC, 10 ³ /μL	8.8±4.3	7.5±2.9	<0.001	10.0±4.6	8.5±3.9	<0.001
Hemoglobin, g/dL	12.1±1.8	13.0±1.7	<0.001	11.6±1.9	12.7±1.7	<0.001
Platelet, 10 ³ /μL	286.7±102.2	262.1±86.2	<0.001	286.5±112.1	261.6±93.6	<0.001
Neutrophil, /μL	6018.5±3864.9	4715.1±2586.1	<0.001	7292.2±4066.3	5704.0±3486.2	<0.001
Lymphocyte, /μL	1798.2±688.6	1950.4±750.0	<0.001	1677.4±723.0	1857.8±868.2	<0.001
Eosinophil, /μL	224.8±283.9	221.3±337.2	0.804	229.9±292.6	225.8±314.4	0.785
Monocyte, /μL	15.5±64.3	19.1±79.0	0.203	800.4±421.9	636.2±363.6	<0.001
Basophil, /μL	32.7±27.8	31.7±22.5	0.352	33.5±30.8	31.5±30.4	0.191
Protein, d/dL	6.8±0.7	6.9±0.6	0.026	6.8±0.8	6.9±0.7	0.001
AST, IU/L	25.6±21.3	24.5±18.0	0.190	28.0±23.6	26.1±26.3	0.082
ALT, IU/L	23.4±23.1	22.1±24.7	<0.001	25.5±26.2	23.9±26.3	<0.001
ALP, IU/L	99.3±80.4	86.3±59.3	<0.001	104.8±91.8	89.9±72.1	<0.001
T-Bil, mg/dL	0.5±0.5	0.5±0.5	0.328	0.6±0.5	0.6±0.6	0.607
GGT, IU/L	59.3±98.1	43.4±77.1	0.016	75.9±77.7	65.5±96.9	0.261
Uric acid, mg/dL	4.7±1.7	5.0±1.5	0.322	4.5±2.1	5.0±1.8	0.439
BUN, mg/dL	15.1±8.2	15.1±6.2	0.001	14.6±9.0	15.6±7.6	<0.001
Creatinine, mg/dL	1.0±1.1	0.9±0.6	0.033	1.0±1.1	0.9±0.7	0.181
Calcium, mg/dL	9.0±0.7	9.1±0.6	0.038	8.8±0.6	8.9±0.6	0.011
Phosphorus, mg/dL	3.5±0.7	3.6±0.6	<0.001	3.3±0.8	3.5±0.7	<0.001
Sodium, mEq/L	138.3±3.5	139.2±3.5	<0.001	137.0±3.7	138.2±3.9	<0.001
Potassium, mEq/L	4.3±0.5	4.3±0.4	0.365	4.2±0.4	4.3±0.4	<0.001
Chloride, mEq/L	101.0±3.9	102.3±3.7	<0.001	100.5±4.1	102.0±4.1	<0.001
Cholesterol, mg/dL	156.6±36.8	168.4±36.9	<0.001	149.8±39.8	165.1±39.6	<0.001

LDL, mg/dL	114.2±33.1	110.1±31.4	0.476	107.5±40.8	109.3±33.0	0.806
HDL, mg/dL	42.3±14.6	46.6±14.8	0.095	41.6±14.3	43.2±14.3	0.562
Triglyceride, mg/dL	112.0±72.2	119.2±62.5	0.494	125.2±67.7	135.0±82.0	0.506

CRP = C-Reactive Protein; WBC = White Blood Cell; AST = Aspartate Aminotransferase; ALT = Alanine Aminotransferase; ALP = Alkaline Phosphatase; T-Bil = Total Bilirubin; GGT = Gamma-glutamyltransferase; BUN = Blood Urea Nitrogen; LDL = Low Density Lipoprotein; HDL = High Density Lipoprotein; $P < 0.05$ is shown in bold.

Supplementary Table 3. The use of antibiotics within 3 days from the day of EBUS-TBNA

Antibiotics	Fever (N=665)	non-Fever (N=5671)	P-value																																			
Antibiotics only before/after EBUS-TBNA, n (%)	0	0																																				
Use of antibiotics, n (%)	38 (5.7)	34 (0.6)	<0.001 ¹																																			
Antibiotics before EBUS-TBNA																																						
Start from the day of EBUS-TBNA, day	1.63	2.24	0.322 ²																																			
Duration, day	3.42	4.35	0.179 ²																																			
Classification, n (%)			0.049 ¹																																			
<table><tr><td>1stCS</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>3rdCS</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>PN+BI</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>QN</td><td></td></tr><tr><td></td><td>3rdCS</td><td></td><td></td><td>ML</td></tr><tr><td></td><td></td><td>PN+BI</td><td>QN</td><td></td></tr><tr><td></td><td></td><td>PN+BI</td><td></td><td>ML</td></tr></table>	1 st CS						3 rd CS						PN+BI						QN			3 rd CS			ML			PN+BI	QN				PN+BI		ML	0	3 (8.8)	
1 st CS																																						
	3 rd CS																																					
		PN+BI																																				
			QN																																			
	3 rd CS			ML																																		
		PN+BI	QN																																			
		PN+BI		ML																																		
	11 (28.9)	4 (11.8)																																				
	10 (26.3)	10 (29.4)																																				
	1(2.6)	7 (20.6)																																				
	2 (5.3)	1 (2.9)																																				
	5 (13.2)	4 (11.8)																																				
	3 (7.9)	0																																				
Others [†]	6 (15.8)	5 (14.7)																																				
Antibiotics after EBUS-TBNA																																						
Start after the day of EBUS-TBNA, day	1.66	1.91	0.176 ²																																			
Duration, day	5.68	3.68	0.127 ²																																			
Classification, n (%)			0.043 ¹																																			
<table><tr><td>3rdCS</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>QN</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>PN+BI</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>CBP</td><td></td></tr><tr><td></td><td>QN</td><td>PN+BI</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>CBP</td><td>GP</td></tr></table>	3 rd CS						QN						PN+BI						CBP			QN	PN+BI						CBP	GP	0	6 (17.6)						
3 rd CS																																						
	QN																																					
		PN+BI																																				
			CBP																																			
	QN	PN+BI																																				
			CBP	GP																																		
	5 (13.2)	7 (20.6)																																				
	10 (26.3)	8 (23.5)																																				
	3 (7.9)	1 (2.9)																																				
	6 (15.8)	2 (5.9)																																				
	6 (15.8)	1 (2.9)																																				
Others [‡]	8 (21.1)	9 (26.5)																																				

EBUS-TBNA = endobronchial ultrasound-guided transbronchial needle aspiration; 1stCS = first generation

cephalosporin; 3rdCS = third generation cephalosporin; PN = penicillin; BI = beta-lactamase inhibitor; QN = quinolone; ML = macrolide; CBP = carbapenem; GP = glycopeptide.

[†]This included ML, incosamide, GP, 3rdCS with 1stCS, 3rdCS with incosamide, 4thCS with incosamide, QN with incosamide, GP with 3rdCS, GP with QN, and CBP with aminoglycoside.

[‡]This included ML, 1stCS, 4thCS, GP, CBP with PN, 3rdCS with ML, 3rdCS with QN, 3rdCS with incosamide, CBP with QN, GP with PN, 1stCS with aminoglycoside, 2ndCS with aminoglycoside, and QN with aminoglycoside.

¹Chi-squared test; ²Student's t-test; $P < 0.05$ is shown in bold.